A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile

Gregory A. Cote, A. Jesse Gore, Samantha D. McElyea, Laura E. Heathers, Huiping Xu, Stuart Sherman, Murray Korc

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

OBJECTIVES:Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) are lacking. We measured the differential expression of select microRNAs (miRNAs) in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls.METHODS:We identified patients (n=215) with treatment-naive PDAC (n=77), CP with bile/pancreatic duct pathology (n=67), and controls (n=71) who had been prospectively enrolled in a Pancreatobiliary Biorepository at the time of endoscopic retrograde cholangiopancreatography or endoscopic ultrasound. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with PDAC, CP, and controls. Panels were derived from the differential expression of 10 candidate miRNAs in plasma or bile. We selected miRNAs having excellent accuracy for inclusion in regression models.RESULTS:Using the training cohort, we confirmed the differential expression of 9/10 miRNAs in plasma (miR-10b,-30c,-106b,-132,-155,-181a,-181b,-196a, and-212) and 7/10 in bile (excluding miR-21,-132, and-181b). Of these, five (miR-10b,-155,-106b,-30c, and-212) had excellent accuracy for distinguishing PDAC. In the training and validation cohorts, the sensitivity/specificity for a PDAC Panel derived from plasma was 95/100% and 100/100%, respectively; in bile, these were 96/100% and 100/100%.CONCLUSIONS:Increased expression of miRNA-10b,-155, and-106b in plasma appears highly accurate in diagnosing PDAC. Additional studies are needed to confirm this Panel and explore its value as a prognostic test.

Original languageEnglish
Pages (from-to)1942-1952
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume109
Issue number12
DOIs
StatePublished - Dec 11 2014

Fingerprint

MicroRNAs
Routine Diagnostic Tests
Bile
Adenocarcinoma
Chronic Pancreatitis
Choledocholithiasis
Endoscopic Retrograde Cholangiopancreatography
Pancreatic Ducts
Bile Ducts
Pancreas
Pathology
Sensitivity and Specificity

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. / Cote, Gregory A.; Gore, A. Jesse; McElyea, Samantha D.; Heathers, Laura E.; Xu, Huiping; Sherman, Stuart; Korc, Murray.

In: American Journal of Gastroenterology, Vol. 109, No. 12, 11.12.2014, p. 1942-1952.

Research output: Contribution to journalArticle

@article{d2501fc714ad4446af6f71615913e21a,
title = "A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile",
abstract = "OBJECTIVES:Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) are lacking. We measured the differential expression of select microRNAs (miRNAs) in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls.METHODS:We identified patients (n=215) with treatment-naive PDAC (n=77), CP with bile/pancreatic duct pathology (n=67), and controls (n=71) who had been prospectively enrolled in a Pancreatobiliary Biorepository at the time of endoscopic retrograde cholangiopancreatography or endoscopic ultrasound. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with PDAC, CP, and controls. Panels were derived from the differential expression of 10 candidate miRNAs in plasma or bile. We selected miRNAs having excellent accuracy for inclusion in regression models.RESULTS:Using the training cohort, we confirmed the differential expression of 9/10 miRNAs in plasma (miR-10b,-30c,-106b,-132,-155,-181a,-181b,-196a, and-212) and 7/10 in bile (excluding miR-21,-132, and-181b). Of these, five (miR-10b,-155,-106b,-30c, and-212) had excellent accuracy for distinguishing PDAC. In the training and validation cohorts, the sensitivity/specificity for a PDAC Panel derived from plasma was 95/100{\%} and 100/100{\%}, respectively; in bile, these were 96/100{\%} and 100/100{\%}.CONCLUSIONS:Increased expression of miRNA-10b,-155, and-106b in plasma appears highly accurate in diagnosing PDAC. Additional studies are needed to confirm this Panel and explore its value as a prognostic test.",
author = "Cote, {Gregory A.} and Gore, {A. Jesse} and McElyea, {Samantha D.} and Heathers, {Laura E.} and Huiping Xu and Stuart Sherman and Murray Korc",
year = "2014",
month = "12",
day = "11",
doi = "10.1038/ajg.2014.331",
language = "English",
volume = "109",
pages = "1942--1952",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile

AU - Cote, Gregory A.

AU - Gore, A. Jesse

AU - McElyea, Samantha D.

AU - Heathers, Laura E.

AU - Xu, Huiping

AU - Sherman, Stuart

AU - Korc, Murray

PY - 2014/12/11

Y1 - 2014/12/11

N2 - OBJECTIVES:Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) are lacking. We measured the differential expression of select microRNAs (miRNAs) in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls.METHODS:We identified patients (n=215) with treatment-naive PDAC (n=77), CP with bile/pancreatic duct pathology (n=67), and controls (n=71) who had been prospectively enrolled in a Pancreatobiliary Biorepository at the time of endoscopic retrograde cholangiopancreatography or endoscopic ultrasound. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with PDAC, CP, and controls. Panels were derived from the differential expression of 10 candidate miRNAs in plasma or bile. We selected miRNAs having excellent accuracy for inclusion in regression models.RESULTS:Using the training cohort, we confirmed the differential expression of 9/10 miRNAs in plasma (miR-10b,-30c,-106b,-132,-155,-181a,-181b,-196a, and-212) and 7/10 in bile (excluding miR-21,-132, and-181b). Of these, five (miR-10b,-155,-106b,-30c, and-212) had excellent accuracy for distinguishing PDAC. In the training and validation cohorts, the sensitivity/specificity for a PDAC Panel derived from plasma was 95/100% and 100/100%, respectively; in bile, these were 96/100% and 100/100%.CONCLUSIONS:Increased expression of miRNA-10b,-155, and-106b in plasma appears highly accurate in diagnosing PDAC. Additional studies are needed to confirm this Panel and explore its value as a prognostic test.

AB - OBJECTIVES:Accurate peripheral markers for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) are lacking. We measured the differential expression of select microRNAs (miRNAs) in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls.METHODS:We identified patients (n=215) with treatment-naive PDAC (n=77), CP with bile/pancreatic duct pathology (n=67), and controls (n=71) who had been prospectively enrolled in a Pancreatobiliary Biorepository at the time of endoscopic retrograde cholangiopancreatography or endoscopic ultrasound. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with PDAC, CP, and controls. Panels were derived from the differential expression of 10 candidate miRNAs in plasma or bile. We selected miRNAs having excellent accuracy for inclusion in regression models.RESULTS:Using the training cohort, we confirmed the differential expression of 9/10 miRNAs in plasma (miR-10b,-30c,-106b,-132,-155,-181a,-181b,-196a, and-212) and 7/10 in bile (excluding miR-21,-132, and-181b). Of these, five (miR-10b,-155,-106b,-30c, and-212) had excellent accuracy for distinguishing PDAC. In the training and validation cohorts, the sensitivity/specificity for a PDAC Panel derived from plasma was 95/100% and 100/100%, respectively; in bile, these were 96/100% and 100/100%.CONCLUSIONS:Increased expression of miRNA-10b,-155, and-106b in plasma appears highly accurate in diagnosing PDAC. Additional studies are needed to confirm this Panel and explore its value as a prognostic test.

UR - http://www.scopus.com/inward/record.url?scp=84927177778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927177778&partnerID=8YFLogxK

U2 - 10.1038/ajg.2014.331

DO - 10.1038/ajg.2014.331

M3 - Article

C2 - 25350767

AN - SCOPUS:84927177778

VL - 109

SP - 1942

EP - 1952

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 12

ER -